A study on therapeutic management of allergic conjunctivitis and assessment of quality of life in patients
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252579Keywords:
Allergic conjunctivitis, Antihistamines, Supportive therapy, Topical corticosteroidsAbstract
Background: Allergic conjunctivitis (AC) is a common ocular condition triggered by exposure to allergens. The primary objective of this study was to evaluate the therapeutic management of patients suffering from allergic conjunctivitis and to determine the prevalence of AC among patients attending an allergy center.
Methods: A retro-prospective, interventional study was conducted, for a six-month period from March to August 2024. Total of 260 patients diagnosed with AC were included from total of 1,523 individuals attending the center. Inclusion criteria focused on patients of all ages undergoing treatment for AC, excluding those with infectious conjunctivitis or other ocular pathologies. Patient data were collected using structured forms that included demographic information, presenting symptoms, other allergic conditions etc. Treatments were categorized into pharmacological, personalized and supportive therapy.
Results: Among all the 1,523 patients, 263 were diagnosed with AC, indicating a prevalence of 17.26%. Allergen testing revealed that dust mites were the leading triggers, followed by pollens. Coexisting allergic conditions were highly prevalent, particularly allergic rhinitis and dermatitis. Pharmacological therapy, like antihistamines and topical corticosteroids, was administered to 86 patients, while 105 patients received personalized treatments. A statistically significant improvement in post-treatment symptom scores was observed, with an effect size of 1.62, indicating high treatment efficacy.
Conclusions: This study highlights the need for early diagnosis, comprehensive allergen evaluation and targeted management in allergic conjunctivitis. The study contributes to the scientific understanding of AC by providing real-world data on allergen prevalence and treatment outcomes.
Metrics
References
Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. European J Ophthalmol. 2010;20(2):257-64. DOI: https://doi.org/10.1177/112067211002000201
Kosrirukvongs P, Visitsunthorn N, Vichyanond P, Bunnag C. Allergic conjunctivitis. Asian Pacif J Aller Immunol. 2001;19(4):237.
Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. InAller Asth Proceed. 2013;34(5):408-20. DOI: https://doi.org/10.2500/aap.2013.34.3695
Del Cuvillo A, Sastre J, Montoro J, Jáuregui I, Dávila I, Ferrer M, et al. Allergic conjunctivitis and H. J Investig Allergol Clin Immunol. 2009;19(1):11-8.
Baig R, Ali AW, Ali T, Ali A, Shah MN, Sarfaraz A, et al. Prevalence of allergic conjunctivitis in school children of Karachi. J Pakistan Med Assoc. 2010;60(5):371.
Bielory L. Allergic conjunctivitis and the impact of allergic rhinitis. Curr Aller Asthama Rep. 2010;10:122-34. DOI: https://doi.org/10.1007/s11882-010-0087-1
Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, et al. Treatment of allergic conjunctivitis: results of a 1- month, single-masked randomized study. European J Ophthalmol. 2010;20(5):811-8. DOI: https://doi.org/10.1177/112067211002000501
Parys W, Blockhuys S, Janssens M. New trends in the treatment of allergic conjunctivitis. Docum Ophthalmolog. 1992;82:353-60. DOI: https://doi.org/10.1007/BF00161023
Kausar A, Akhtar N, Akbar N. Epidemiological Aspects of Allergic Conjunctivitis. J Ayub Medical College Abbottabad-Pakistan. 2022;1;34(1):869. DOI: https://doi.org/10.55519/JAMC-01-9432
Memariani H, Memariani M, Ghasemian A. Quercetin as a Promising Antiprotozoan Phytochemical: Current Knowledge and Future Research Avenues. BioMed Res Int. 2024;29;264. DOI: https://doi.org/10.1155/2024/7632408
Belfort R, Marbeck P, Hsu CC, Freitas D. Epidemiological study of 134 subjects with allergic conjunctivitis. Acta Ophthalmologica Scandinavica. 2000;78:38-40. DOI: https://doi.org/10.1034/j.1600-0420.2000.078s230038.x
Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Aller, Asthma Immunol. 2020;124(2):118-34. DOI: https://doi.org/10.1016/j.anai.2019.11.014
Vazirani J, Shukla S, Chhawchharia R, Sahu S, Gokhale N, Basu S. Allergic conjunctivitis in children: current understanding and future perspectives. Current Opin Aller Clin Immunol. 2020;20(5):507-15. DOI: https://doi.org/10.1097/ACI.0000000000000675
Kuruvilla M, Kalangara J, Lee FE. Neuropathic pain and itch mechanisms underlying allergic conjunctivitis. J Investig Allergol Clin Immunol. 2019;29(5):349-56. DOI: https://doi.org/10.18176/jiaci.0320
Ridolo E, Montagni M, Caminati M, Senna G, Incorvaia C, Canonica GW. Emerging drugs for allergic conjunctivitis. Expert Opinion on Emerging Drugs. 2014;19(2):291-302. DOI: https://doi.org/10.1517/14728214.2014.902443